Trials / Recruiting
RecruitingNCT06258668
Real-World Safety and Effectiveness of Sotyktu (Deucravacitinib) in Patients With Moderate-to-Severe Plaque Psoriasis in Korea
Sotyktu (Deucravacitinib) Post-Marketing Surveillance in Korean Patients With Moderate-to-Severe Plaque Psoriasis
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 505 (estimated)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- —
Summary
The purpose of this observational study is to describe the safety and effectiveness of deucravacitinib in participants in Korea that have been diagnosed with moderate-to-severe plaque psoriasis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Deucravacitinib | As per product label |
Timeline
- Start date
- 2024-08-21
- Primary completion
- 2028-09-30
- Completion
- 2028-09-30
- First posted
- 2024-02-14
- Last updated
- 2024-11-06
Locations
2 sites across 1 country: South Korea
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06258668. Inclusion in this directory is not an endorsement.